ZA201501123B - Improved methods for treating cancer with reduced renal toxicity - Google Patents

Improved methods for treating cancer with reduced renal toxicity

Info

Publication number
ZA201501123B
ZA201501123B ZA2015/01123A ZA201501123A ZA201501123B ZA 201501123 B ZA201501123 B ZA 201501123B ZA 2015/01123 A ZA2015/01123 A ZA 2015/01123A ZA 201501123 A ZA201501123 A ZA 201501123A ZA 201501123 B ZA201501123 B ZA 201501123B
Authority
ZA
South Africa
Prior art keywords
treating cancer
improved methods
renal toxicity
reduced renal
toxicity
Prior art date
Application number
ZA2015/01123A
Other languages
English (en)
Inventor
Teni Boulikas
George Stathopoulos
Original Assignee
Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teni Boulikas filed Critical Teni Boulikas
Publication of ZA201501123B publication Critical patent/ZA201501123B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2015/01123A 2012-08-13 2015-02-18 Improved methods for treating cancer with reduced renal toxicity ZA201501123B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Publications (1)

Publication Number Publication Date
ZA201501123B true ZA201501123B (en) 2020-02-26

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/01123A ZA201501123B (en) 2012-08-13 2015-02-18 Improved methods for treating cancer with reduced renal toxicity

Country Status (13)

Country Link
US (1) US20150258140A1 (enExample)
EP (1) EP2882420A4 (enExample)
JP (1) JP2015528446A (enExample)
CN (1) CN104736143A (enExample)
AU (1) AU2012387681A1 (enExample)
BR (1) BR112015003111A2 (enExample)
CA (1) CA2882156A1 (enExample)
EA (1) EA201590325A1 (enExample)
IN (1) IN2015KN00375A (enExample)
MA (1) MA37931A1 (enExample)
SG (1) SG11201501146VA (enExample)
WO (1) WO2014027996A1 (enExample)
ZA (1) ZA201501123B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728724A (en) * 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Also Published As

Publication number Publication date
EP2882420A4 (en) 2016-06-01
JP2015528446A (ja) 2015-09-28
CA2882156A1 (en) 2014-02-20
BR112015003111A2 (pt) 2017-10-10
MA37931A1 (fr) 2016-07-29
CN104736143A (zh) 2015-06-24
IN2015KN00375A (enExample) 2015-07-10
SG11201501146VA (en) 2015-05-28
AU2012387681A1 (en) 2015-03-05
EA201590325A1 (ru) 2015-09-30
WO2014027996A1 (en) 2014-02-20
US20150258140A1 (en) 2015-09-17
EP2882420A1 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
IL272206A (en) Combined treatment for cancer
IL267242B (en) Cancer treatment
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
GB201208309D0 (en) Complexes
PL2707030T3 (pl) Metody leczenia raka
IL228644A0 (en) Cancer treatment methods
HUE049697T2 (hu) Eljárás rák szkrínelésére
IL254964A0 (en) A method for treating breast cancer
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
IL245037B (en) Treatment for pancreatic cancer
PL3016682T3 (pl) Sposoby leczenia nowotworu
ZA201406172B (en) Compounds and methods for treating leukemia
DK2872176T3 (en) Cancer treatment
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
ZA201504169B (en) Anti-adam28 antibody for treating cancer
GB201104522D0 (en) Complexes
HUE048502T2 (hu) Kondroitin komplexek transzkután abszorpcióra
GB201220901D0 (en) CD44v6-derived peptides for treating pancreatic cancer
SG11201501146VA (en) Improved methods for treating cancer with reduced renal toxicity
GB201222563D0 (en) Cancer treatment
AU2012901918A0 (en) Methods for treating cancer
IL239231A0 (en) Combined cancer treatment
GB201210358D0 (en) Complexes
GB201118482D0 (en) Treating tumours
GB201218799D0 (en) Compounds